News

Clinical Trials Arena5d
MSD’s Enflonsia receives FDA approval for RSV prophylaxis
MSD's Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...
Fierce Pharma8d
Merck scores FDA nod for Enflonsia, setting up RSV market battle vs. Sanofi and AstraZeneca's Beyfortus
Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...
PharmExec7d
FDA Approves Merck’s Enflonsia to Prevent Respiratory Syncytial Virus
Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...
Pulmonology Advisor4d
Enflonsia Approved for RSV Disease Prevention in Infants
The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...
GlobalData on MSN7d
MSD receives FDA approval for Enflonsia to prevent RSV
The approval was based on data from the pivotal Phase IIb/III CLEVER trial which assessed a single dose of the antibody.
Medindia on MSN4d
FDA Approves ENFLONSIA to Shield Infants From RSV
In a major boost for infant health, the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA (clesrovimab-cfor) , a ...
KIVI-TV4d
FDA approves Merck’s Enflonsia to prevent RSV in infants
The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...
Zacks.com on MSN7d
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.